Literature DB >> 30707379

Amoxicillin/clavulanic acid+aminoglycoside as empirical antibiotic treatment in severe community-acquired infections with diagnostic uncertainty.

Johan Courjon1,2,3, David Chirio4, Elisa Demonchy4, Céline Michelangeli4, Nicolas Degand5, Pierre-Marie Roger4,6,7.   

Abstract

Diagnostic uncertainty is common in the emergency room and multidrug-resistant bacteria emerge in the community setting, implying to establish the most efficient empirical antibiotic therapy (eEAT). Our aim was to identify such eEAT, considering that in case of DU with severe clinical presentation, most prescribers would propose an empiric combination (EC). The medical dashboard of our ward records prospectively 28 characteristics of each hospitalization including hospitalization motive, final diagnosis, and all antibiotics prescribed. All patients with community-acquired bacteremia (CAB) were included. DU was defined by a discrepancy between suspected diagnosis in the emergency room and final diagnosis. eEAT was defined by in vitro activity of at least one prescribed compound. Finally, independently from the dashboard, we retrospectively compared 2 CTs: amoxicillin/clavulanic acid (AMC)+gentamicin (G) and cefotaxime (3GC)+G. One thousand thirty-four patients with a final diagnosis of CAB were identified from July 2005 to June 2018, including 357 DU (35%) at baseline. eEAT (n = 553) was associated with a trend towards a lower death rate compared to inefficient therapies: 5.4 vs 10.0% (p = 0.053), and effective antibiotic reassessment was the most protective factor against an unfavorable outcome: 0.34 (0.16-0.71). Bacteria involved in case of UD were resistant to AMC+G and to 3GC+G in 8.1% and 12.8% of patients, respectively. Diagnostic uncertainty was a frequent event requiring antibiotic reassessment. As the latter was not systematically realized, the best eEAT is required and AMC+aminoglycoside should be considered.

Entities:  

Keywords:  Bacteremia; Community-acquired infection; ESBL Enterobacteriaceae; Empirical antibiotic therapy; Outcome

Mesh:

Substances:

Year:  2019        PMID: 30707379     DOI: 10.1007/s10096-019-03496-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.

Authors:  P L Winokur; R Canton; J M Casellas; N Legakis
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  Diagnostic Errors that Lead to Inappropriate Antimicrobial Use.

Authors:  Gregory A Filice; Dimitri M Drekonja; Joseph R Thurn; Galen M Hamann; Bobbie T Masoud; James R Johnson
Journal:  Infect Control Hosp Epidemiol       Date:  2015-05-18       Impact factor: 3.254

Review 3.  Optimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapy.

Authors:  Gloria Vazquez-Grande; Anand Kumar
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

Review 4.  Ageing and infection.

Authors:  Gaëtan Gavazzi; Karl-Heinz Krause
Journal:  Lancet Infect Dis       Date:  2002-11       Impact factor: 25.071

5.  Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.

Authors:  Agnès Lefort; Xavière Panhard; Olivier Clermont; Paul-Louis Woerther; Catherine Branger; France Mentré; Bruno Fantin; Michel Wolff; Erick Denamur
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

6.  Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study.

Authors:  Nikolay P Braykov; Daniel J Morgan; Marin L Schweizer; Daniel Z Uslan; Theodoros Kelesidis; Scott A Weisenberg; Birgir Johannsson; Heather Young; Joseph Cantey; Arjun Srinivasan; Eli Perencevich; Edward Septimus; Ramanan Laxminarayan
Journal:  Lancet Infect Dis       Date:  2014-11-17       Impact factor: 25.071

Review 7.  Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.

Authors:  Benjamin A Rogers; Hanna E Sidjabat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2010-11-16       Impact factor: 5.790

8.  Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival.

Authors:  Jordi Vallés; Jordi Rello; Ana Ochagavía; José Garnacho; Miguel Angel Alcalá
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

9.  Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age.

Authors:  D Marchaim; R Zaidenstein; T Lazarovitch; Y Karpuch; T Ziv; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-05       Impact factor: 3.267

Review 10.  World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections.

Authors:  Massimo Sartelli; Mark A Malangoni; Addison K May; Pierluigi Viale; Lillian S Kao; Fausto Catena; Luca Ansaloni; Ernest E Moore; Fred A Moore; Andrew B Peitzman; Raul Coimbra; Ari Leppaniemi; Yoram Kluger; Walter Biffl; Kaoru Koike; Massimo Girardis; Carlos A Ordonez; Mario Tavola; Miguel Cainzos; Salomone Di Saverio; Gustavo P Fraga; Igor Gerych; Michael D Kelly; Korhan Taviloglu; Imtiaz Wani; Sanjay Marwah; Miklosh Bala; Wagih Ghnnam; Nissar Shaikh; Osvaldo Chiara; Mario Paulo Faro; Gerson Alves Pereira; Carlos Augusto Gomes; Federico Coccolini; Cristian Tranà; Davide Corbella; Pietro Brambillasca; Yunfeng Cui; Helmut A Segovia Lohse; Vladimir Khokha; Kenneth Yy Kok; Suk-Kyung Hong; Kuo-Ching Yuan
Journal:  World J Emerg Surg       Date:  2014-11-18       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.